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Introduction: Previous studies have shown that atrial ﬁbrillation (AF) recurrence after
pulmonary vein (PV) isolation depends on various factors; however, the eﬀect of cigarette
smoking on AF recurrence after PV isolation has not been investigated.
Methods and Results: Fifty-nine consecutive patients with drug-refractory AF (48 men and
11 women, mean age: 60 11 years) who underwent PV isolation were included. The
patients were divided into two groups: the non-smoker group, i.e., ‘‘never smokers (n ¼ 29),’’
and the smoker group consisting of 30 patients who were either ‘‘former smokers (n ¼ 15)’’ or
‘‘current smokers (n ¼ 15)’’. The diameter of all four PVs and the left atrial volume tended to
be larger in the smoker group. During the mean follow-up period of 306 95 days, the AF
recurrence rate was higher in the smoker group than in the non-smoker group (43% vs. 14%,
p < 0:05). The relative risk of AF recurrence associated with smoking was 3.19 (95% CI 1.23
to 8.27, p ¼ 0:017). The AF recurrence rate was increased in both current smokers (40%) and
former smokers (47%) compared to never smokers (14%).
Conclusions: AF recurrence after PV isolation was signiﬁcantly higher in the smoking
patients. The substrate of AF may be worsened by exposure to cigarette smoking.
(J Arrhythmia 2010; 26: 21–29)
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Introduction
Atrial ﬁbrillation (AF) is the most common
tachyarrhythmia encountered in clinical practice.
Pulmonary vein (PV) isolation by radiofrequency
catheter ablation has been proposed as a curative
treatment for drug-refractory AF.1–4) Although the
success rate after PV isolation in patients with AF
has improved to more than 80%, the recurrence of
AF after ablation is still unacceptable, especially in
patients with persistent AF. Recovery of conduction
across the PV isolating lesion is the most frequent
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cause of arrhythmia recurrence after PV isolation.5–7)
Previous studies have shown that AF recurrence after
PV isolation depends on various factors such as type
of AF, duration of AF, left atrial volume, and atrial
ﬁbrosis or scarring.8–11)
AF may be caused by many cardiac and non-
cardiac conditions, including myocardial infarction,
valvular heart disease, cardiomyopathy, hyperten-
sion, diabetes mellitus, and thyroid disease. Recent-
ly, several factors playing a role in the genesis of AF
have gained attention, including obesity, sleep
apnea, alcohol abuse, genetic factors, inﬂammation,
and cigarette smoking.12) Heeringa et al.13) demon-
strated that current smoking and past smoking are
both associated with an increased risk of AF, but the
eﬀect of smoking on AF recurrence after catheter
ablation has not been investigated. The present study
aims to clarify the eﬀect of smoking on AF
recurrence after a PV isolation procedure in patients
with AF.
Methods
Study population
This study included 59 consecutive patients with
drug-refractory AF (48 men and 11 women, mean
age: 60 11 years) who underwent PV isolation in
our institution between April 2006 and January 2008.
Patients who had previously undergone an ablation
procedure for AF were excluded. Information on
smoking behavior was obtained from the medical
record. Patients were classiﬁed as current smokers,
former smokers, or never smokers. By deﬁnition, the
term ‘‘current smokers’’ was applied to patients who
were active smokers after enrollment; ‘‘former
smokers’’ to patients who had smoked in past but
had quit before their baseline examination, and
‘‘never smokers’’ to patients who had never smoked
in their lifetime. The patients were divided into two
groups: the non-smoker group comprising 29 pa-
tients who were ‘‘never smokers’’ and the smoker
group consisting of 30 patients who were ‘‘former-
smokers (n ¼ 15)’’ and ‘‘current smokers (n ¼ 15).’’
Electrophysiological study
All patients provided written informed consent.
Anticoagulation therapy was not discontinued in any
of the patients, and transesophageal echocardiogra-
phy was performed to exclude any atrial thrombi
before the procedure. The left atrial diameter was
measured by M-mode in a parasternal long-axis
view, and left ventricular ejection fraction was
assessed by transthoracic echocardiography. Three-
dimensional (3D) multi-slice computerized tomog-
raphy (MSCT) scans were performed to visually
deﬁne the anatomy of the left atrium and pulmonary
veins. All patients underwent an electrophysiolog-
ical study and catheter ablation in a fasting state.
The ablation procedure was performed under seda-
tion with a continuous infusion of propofol. Two
multipolar electrode catheters were placed in the
superior vena cava (SVC) and the cavotricuspid
isthmus (CTI) via the femoral vein. A decapolar
electrode catheter was inserted into the coronary
sinus (CS) via the subclavian vein. The left atrium
was accessed by single transseptal puncture using a
Brockenbrough needle (Cook Inc., Bloomington,
Indiana, USA) and an 8-F Mullins sheath (St. Jude
Medical, Inc., St. Paul, Minnesota) via the right
femoral vein, and pulmonary venography was
performed to obtain the anatomical information
through an injection of a contrast medium via three
long sheaths (8-F and 8.5-F SR0 type Schwartz
sheath introducer, and 8-F Mullins sheath, St. Jude
Medical, Inc., St. Paul, Minnesota, USA) after
intravenous administration of adenosine triphosphate
(ATP). Intravenous heparin was administered to
maintain an activated clotting time of >300 seconds
after the atrial transseptal puncture. Two circular
mapping catheters (Lasso, Biosense Webster, Inc.
Diamond Bar, CA, USA) were placed in the superior
and inferior pulmonary veins, respectively. Intra-
cardiac electrograms were recorded on a computer-
based digital recorder system (EP WorkMate Sys-
tem, St. Jude Medical, Inc., St. Paul, Minnesota,
USA). Catheter ablation procedures were performed
in all patients using a 3D electroanatomical mapping
system (CARTO, Biosense Webster, Inc. Diamond
Bar, CA, USA). Before PV isolation, we constructed
a whole left atrial 3D geometry by obtaining contact
bipolar electrograms of the left atrial endocardium
during coronary sinus pacing or atrial ﬁbrillation.
The left atrial volume was calculated automatically
from the geometry constructed with the electro-
anatomical mapping system. An additional left atrial
substrate modiﬁcation strategy was devised for cases
with enlarged left atrium, irrespective of the type of
AF. This strategy is consistent with routine practice
in our laboratory.
Radiofrequency catheter ablation
All patients underwent extensive encircling PV
isolation (EEPVI) and CTI linear ablation routinely,
followed by an additional ablation in some patients
with enlarged left atrium. Continuous circumferen-
tial lesions were created encircling the left and right
PV ostia guided by a CARTO system using a 4-mm-
tip ablation catheter (Navistar, Biosense Webster,
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Inc. Diamond Bar, CA, USA) or an 8-mm-tip
ablation catheter (Ablaze, Japan Lifeline Co., Ltd.,
Tokyo, Japan). The maximum temperature was set to
53 C, and a maximum power of 35W was applied.
The radiofrequency delivery was applied for 30
seconds at each site. Electrophysiology tracings were
then analyzed to search for any gaps on the circular
lesion that were subsequently targeted by radio-
frequency ablation.
The endpoint of the PV isolation procedure was
the bidirectional block between the PV and the
left atrium, with elimination of all recordable PV
potentials conﬁrmed by Lasso catheter and demon-
stration of exit block by circumferential pacing at
5mA output and 2ms duration from Lasso catheter.
After the isolation of ipsilateral PVs, with the
bidirectional block, 20mg of ATP was injected
during the isoproterenol infusion to reveal dormant
conduction. All veins were remapped to conﬁrm
isolation after 30 to 60 minutes.
After completing the EEPVI, the CTI was also
ablated to create a bidirectional block. The CTI
ablation was performed with an 8-mm-tip ablation
catheter (Ablaze) with a maximum power of 50W,
and temperatures of up to 63 C with the dragging
technique. The bidirectional block of the CTI was
conﬁrmed by pacing from the coronary sinus and
lower lateral right atrium at baseline and after the
isoproterenol infusion.
Left atrial substrate modiﬁcation targeting com-
plex fractionated atrial electrograms were carried out
in 9 patients, and a linear ablation for the lateral
mitral isthmus was performed in one patient.
Post-ablation management and follow-up
After the procedure, all patients continued the
previously prescribed antiarrhythmic drugs and
warfarin for at least 3 months. Patients were seen
on an outpatient basis 1 and 3 months after the
procedure and every 3 months thereafter. Patients
were questioned about their symptoms at each visit,
and a 24-hour ambulatory Holter electrocardiogram
and a routine 12-lead surface electrocardiogram
were performed 1, 3, 6, and 12 months after ablation.
A blanking period of 3 months was applied when
AF recurrences were assessed. AF recurrence was
deﬁned as an episode lasting more than 30 seconds.
New-onset atrial tachycardia and atrial ﬂutter were
also deﬁned as recurrence.
Statistical analysis
Continuous variables are expressed as mean 
standard deviation (SD). Continuous variables of
groups were compared using an unpaired t test.
Non-normally distributed variables (duration of AF
history) were compared with a Mann-Whitney U
test. Freedom from AF was determined and com-
pared using a Kaplan-Meier analysis and log-rank
test. The multivariable Cox regression model for
recurrence of AF was created by forcing the
following into the model: age, sex, type of AF, left
atrial diameter, left atrial volume, treatment with
digitalis, and smoking status. The results of these
analyses were summarized as hazard ratios with 95%
conﬁdence intervals (CIs). A probability value
<0:05 was considered statistically signiﬁcant. All
statistical analyses were performed using SPSS
software version 11.01J for windows (SPSS Japan,
Inc., Tokyo, Japan).
Results
Patient characteristics (Table 1)
Clinical characteristics of the patients are shown
in Table 1. All PVs in each patient were electrically
isolated. Thirty-nine patients (66%) had paroxysmal
AF and 20 patients (34%) had persistent AF. Of the
59 patients, 35 (59%) were considered to have lone
AF, i.e., AF without an underlying disorder. In the
present study, 4 patients (7%) had a history of heart
failure, 18 (31%) had hypertension, 11 (19%) had
diabetes mellitus, and 5 (8%) had a history of stroke
or transient ischemic attacks. Forty-six patients
(78%) had a CHADS(2) (congestive heart failure,
hypertension, age > or ¼ 75 years, diabetes mellitus,
and prior stroke or transient ischemic attacks) score
< or ¼ 1.
Mean left atrial diameter was 38 7mm, and
mean left ventricular ejection fraction was 63%
15%. Mean left atrial volume calculated by the
CARTO system was 116 37ml. Mean follow-up
period was 306 95 days.
Comparison of patient characteristics with or
without smoking
The clinical characteristics of the patients in both
groups are given in Table 1. Except for gender, no
signiﬁcant diﬀerences were found in the other
characteristics: age, type of AF, left atrial diameter,
and left ventricular ejection fraction. The smoker
group consisted almost entirely of men (97%). The
smoker group had a tendency of high prevalence of
lone AF (70%). Twelve patients of 29 patients in the
non-smoker group and 6 patients of 30 patients in the
smoker group had a history of hypertension; how-
ever, the diﬀerences were not statistically signiﬁcant
(41% vs. 20%, p ¼ 0:10). In the smoker group, 8
patients (27%) had a history of diabetes mellitus.
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The median duration of AF history was similar
between the two groups (36 months vs. 36 months,
p ¼ 0:50). Additional left atrial substrate ablation,
i.e., complex fractionated electrogram-guided abla-
tion or mitral isthmus linear ablation was performed
in 3 patients in the non-smoker group and 7 patients
in the smoker group, respectively (p ¼ 0:47). The
follow-up periods were comparable between the
non-smoker group and smoker groups (327 82
days vs. 286 104 days, p ¼ 0:10).
Baseline medication
The baseline medical treatment regimens of the
study patients are shown in Table 2. There were no
signiﬁcant diﬀerences in the frequency of the
administration of antiarrhythmic drugs, angioten-
sin-converting enzyme inhibitors, angiotensin II
receptor blockers, beta-blockers, calcium blockers,
or HMG-CoA reductase inhibitors (statin). Treat-
ment with digitalis was used with less frequency in
the non-smoker group.
Effect of smoking on pulmonary vein diameter
and left atrial volume
The diameter of all four PVs, measured by MSCT,
was larger in the smoker group (LSPV: 22:2 3:6
mm vs. 20:4 3:4mm, p ¼ 0:07, LIPV: 19:4 3:2
mm vs. 18:1 3:2mm, p ¼ 0:14, RSPV: 22:0 4:4
mm vs. 21:1 4:7mm, p ¼ 0:45, RIPV: 19:0 3:2
mm vs. 17:7 4:1mm, p ¼ 0:20); however, the
diﬀerence was not statistically signiﬁcant. The left
atrial volume, calculated by the CARTO system,
had a tendency to be larger in the smoker group
(124 35ml vs. 108 39ml, p ¼ 0:11).
High sensitive C-reactive protein (hs-CRP) and
smoking status in patients with AF
We also evaluated blood samples obtained from
the patients before ablation. The serum hs-CRP
levels were higher in the smoker group than in the
non-smoker group; however, the diﬀerence was not
statistically signiﬁcant (0:057 0:094mg/dl vs.
0:047 0:113mg/dl, p ¼ 0:79).
Table 1 Comparison of patient characteristics with and without smoking
Total Non-smoker group Smoker group p value
n ¼ 59 n ¼ 29 n ¼ 30
Age, (years) 60 11 60 13 61 10 0.81
Male/Female 48/11 19/10 29/1 <0.05
Type of AF, n (%) 1.00
Paroxysmal 39 (66%) 19 (66%) 20 (67%)
Persistent 20 (34%) 10 (34%) 10 (33%)
Lone atrial ﬁbrillation, n (%) 35 (59%) 14 (48%) 21 (70%) 0.12
CHF, n (%) 4 (7%) 3 (10%) 1 (3%) 0.35
HTN, n (%) 18 (31%) 12 (41%) 6 (20%) 0.10
DM, n (%) 11 (19%) 3 (10%) 8 (27%) 0.18
Stroke, n (%) 5 (8%) 1 (3%) 4 (9%) 0.35
Left atrial diameter, (mm) 38 7 40 7 38 7 0.32
Left atrial volume, (ml) 116 37 108 39 124 35 0.11
LVEF, (%) 63 15 63 16 63 13 0.99
Pulmonary vein diameter, (mm)
LSPV 20.4  3.4 22.2  3.6 0.07
LIPV 18.1  3.2 19.4  3.2 0.14
RSPV 21.1  4.7 22.0  4.4 0.45
RIPV 17.7  4.1 19.0  3.2 0.20
High-sensitive CRP (mg/dl) 0.047  0.113 0.057  0.094 0.79
History of AF, (months)y Median 36 Median 36 0.50
Follow-up, (days) 306 95 327 82 286 104 0.10
Values are expressed as mean  standard deviation.
AF: atrial ﬁbrillation, LVEF: left ventricular ejection fraction, CHF: congestive heart failure, HTN:
hypertension, DM: diabetes mellitus, LSPV: left superior pulmonary vein, LIPV: left inferior pulmo-
nary vein, RSPV: right superior pulmonary vein, RIPV: right inferior pulmonary vein, yMann-Whitney
U test
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Inter and intra atrium conduction time measure-
ment
The inter-conduction time between right atrium
and left atrium (earliest activation that recorded from
SVC catheter to latest activation that recorded from
CS catheter) was evaluated in 53 patients. During
sinus rhythm, right atrial to left atrial conduction
time was similar between non-smoker group
(n ¼ 27) and smoker group (n ¼ 26); (105:9 4:9
ms vs. 107:8 6:0ms, p ¼ 0:80). The intra-conduc-
tion time in the left atrium was also measured from
the electroanatomical maps during CS pacing
rhythm (pacing cycle length 600ms) using CARTO
mapping system. The total left atrial activation time
was 112:8 6:6ms in non-smoker group (n ¼ 14)
and 126:3 8:6ms in smoker group (n ¼ 12),
respectively (p ¼ 0:22). The total left atrial activa-
tion time was prolonged in smoker group; however,
the diﬀerence was not statistically signiﬁcant.
Smoking and AF recurrence after catheter abla-
tion
During the mean follow-up of 306 95 days, 42
(71%) of the 59 patients were free of symptoms and
had no evidence of atrial tachyarrhythmia. When the
type of AF was analyzed by a Kaplan-Meier survival
curve, no signiﬁcant diﬀerences in the rate of
recurrence of AF was observed between patients
with paroxysmal and persistent AF (26% vs. 35%,
p ¼ 0:63; Figure 1). AF recurrence after PV isolation
was higher in the smoker group than in the non-
smoker group (43% vs. 14%, p < 0:05; Figure 2).
The relative risk of AF recurrence associated with
smoking was 3.19 (95% CI 1.23 to 8.27, p ¼ 0:017).
Adjustment for sex, type of AF, left atrial diameter,
left atrial volume, and treatment with digitalis did
not signiﬁcantly change the relative risk (hazard
ratio = 3.16, 95% CI 1.03 to 9.71, P ¼ 0:044). The
Kaplan-Meier survival curves of freedom from AF
recurrence in never smokers, former smokers, and
current smokers are shown in Figure 3. The overall
rate of recurrence of AF was signiﬁcantly increased
among current smokers (40%) and former smokers
(47%) compared to never smokers (14%, p < 0:05).
As shown in Figure 3, the AF free survival rate was
signiﬁcantly higher in never smokers than in former
smokers (86% vs. 53%, p < 0:05). In current
smokers, the AF free survival rate was lower than
that in never smokers, but the diﬀerence between the
two categories was not statistically signiﬁcant (60%
vs. 86%, p ¼ 0:07).
A second ablation procedure was performed in 12
(70%) of 17 patients who had AF recurrence. All
(100%) of them exhibited at least one PV reconnec-
tion in the previous isolated PVs. At repeat ablation,
2:3 0:3 veins per patient in the non-smoking group
and 2:8 0:3 veins per patient in the smoking group
were reconnected (p ¼ 0:48).
Table 2 Comparison of the medical treatment for the smoker and nonsmoker groups
Nonsmoker group
(n ¼ 29)
Smoker group
(n ¼ 30) p value
ACEI or ARB 13 (45%) 10 (33%) 0.37
Beta blocker 4 (14%) 2 (7%) 0.32
Calcium channel blocker 14 (48%) 13 (43%) 0.70
Digitalis 1 (3%) 7 (23%) <0.05
Statin 6 (21%) 8 (27%) 0.59
Antiarrhythmic drugs total
Without AADs 12 (41%) 7 (23%) 0.14
With AADs 17 (59%) 23 (77%)
Cibenzoline 3 2 1
Disopyramide 1 1 0
Quinidine 1 0 1
Pilsicainide 21 9 12
Flecainide 3 1 2
Bepridil 22 9 13
Sotalol 2 1 1
AADs combination 6 (21%) 7 (23%) 1.00
ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin II receptor blocker, AADs: antiarrhythmic
drugs
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Discussion
Main ﬁndings
In the present study, we show that the recurrence
rate of AF after PV isolation is signiﬁcantly higher
in smoking patients than in non-smoking patients
during a follow-up of approximately 1 year. The
present study results show that both current and past
smoking of cigarettes is associated with an increased
risk of AF recurrence after catheter ablation. PV
diameter and left atrial volume tended to be larger in
smoking patients than in non-smoking patents. These
ﬁndings indicate that the substrate of AF may be
worsened by exposure to cigarette smoking.
Previous studies
Smoking is a powerful independent predictor of
morbidity and mortality in high risk cardiac patients
such as in coronary heart disease with left ventricular
dysfunction.14) Cigarette smoking has adverse eﬀects
on blood pressure and sympathetic tone, and it
causes a reduction in the myocardial oxygen supply
through several other mechanisms, including impair-
ment of the endothelium-dependent coronary artery
vasodilatation caused by dysfunctional endothelial
nitric oxide biosynthesis.15,16) Nicotine produces a
marked elevation in serum catecholamine concen-
tration that is potentially arrhythmogenic.17) The
association between smoking and risk of AF has
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Figure 1 Kaplan-Meier analysis of free-
dom from atrial ﬁbrillation after pulmonary
vein isolation during follow-up in patients
with paroxysmal atrial ﬁbrillation (solid line)
and in patients with persistent atrial ﬁbrilla-
tion (dashed line).
The analysis time begins after a 3-month
blanking period. The diﬀerence between the
two groups was not signiﬁcant (p ¼ 0:43). The
table below the graph represents the number of
patients at risk in each group at the beginning of
each time interval.
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Figure 2 Kaplan-Meier analysis of free-
dom from atrial ﬁbrillation recurrence in
patients in the non-smoker group (solid line)
and patients in the smoker group (dashed
line). The analysis time begins after a 3-
month blanking period.
The curves demonstrate a signiﬁcantly greater
rate of recurrent atrial ﬁbrillation in the smoker
group (43%) than in the non-smoker group
(14%, p < 0:05). The table below the graph
represents the number of patients at risk in each
group at the beginning of each time interval.
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been reported previously in several studies. In the
Framingham Heart study,18) cigarette smoking was
found to be a potential risk factor for AF in women,
but statistical signiﬁcance could not be reached in
multivariate analyses. The Copenhagen City Heart
Study,19) the Renfrew/Paisley Study,20) and the
Danish Direct Cancer and Health Study21) revealed
no associations between smoking and AF. On the
other hand, the Rotterdam Study13) indicated that
smoking is associated with an increased risk of AF.
In this prospective, population-based study, the
results show that past smoking is an equally strong
risk factor as current smoking. In our present study,
we demonstrate that both current and past smoking
of cigarettes is associated with an increased risk of
AF recurrence after catheter ablation. Goldenberg
et al22) analyzed the eﬀect of cigarette smoking in a
cohort of 717 patients with an implantable cardi-
overter deﬁbrillator (ICD) from the MADIT II study
on appropriate and inappropriate ICD therapy. This
study revealed that continued cigarette smoking
signiﬁcantly elevates the risk of ventricular tachy-
cardia or ﬁbrillation and can also be associated with
an increased risk of rapid supraventricular arrhyth-
mias.
Recently, Goette et al23) investigated the amount
of atrial ﬁbrosis and the expression patterns of
collagens in atrial appendages of patients admitted
for coronary bypass graft surgery without history of
AF. They showed that nicotine exposure accelerates
atrial collagen accumulation, leading to atrial ﬁb-
rosis. Nicotine base induced collagen III mRNA
expression, which is the major constituent of atrial
ﬁbrosis in smokers, in a concentration-dependent
manner. The authors concluded that atrial ﬁbrosis by
itself provides an arrhythmogenic substrate, which
may increase the likelihood of occurrence of AF,
including postoperative AF. Tuan et al24) reported
that in patients with AF who underwent PV isolation,
the mean peak-to-peak bipolar voltage of the right
atrium was lower in the patients with a previous
history of smoking than in those without a history of
smoking. Further, the total activation time of the
right atrium was longer in smoking patients than in
non-smoking patients. The authors suggested that
smoking may change the substrate properties and
perpetuate the AF. In our results, PV diameter and
left atrial volume had a tendency to be larger in the
smoking patient group when compared to the non-
smoking patient groups. The association between
smoking and conduction time in the atrium was not
revealed statistically in our study. CARTO activation
map before ablation was obtained during CS pacing
in only 26 of 59 patients and during atrial ﬁbrillation
in the remaining patients. These ﬁndings need to be
assessed in a larger number of patients.
Study limitations
This study has the following limitations. (1) The
most important limitation is that we did not analyze
all of the mechanisms of AF recurrence after PV
isolation, such as whether the recurrence resulted
from a recovery of conduction between a pulmonary
vein and the left atrium or if it occurred despite the
maintenance of PV isolation. In our study, a second
ablation procedure was performed in 70% of patients
who had AF recurrence. All of them exhibited at
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Figure 3 Kaplan-Meier analysis of free-
dom from atrial ﬁbrillation recurrence in
never smokers (solid line), former smokers
(dotted line), and current smokers (dashed
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blanking period. The table below the graph
represents the number of patients at risk in each
group at the beginning of each time interval.
Fukamizu S Cigarette smoking and atrial ﬁbrillation recurrence after ablation
27
least one PV reconnection in the previous isolated
PVs. Furthermore, there was no signiﬁcant diﬀer-
ence in the number of reconnected PVs between the
non-smoker group and the smoker group (2:3 0:3
veins per patient vs. 2:8 0:3 veins per patient,
P ¼ 0:48). These ﬁndings suggest that the eﬀect of
smoking may have an inﬂuence on the substrate of
AF. (2) In our study, we did not obtain data on the
number of cigarettes/cigarette packs smoked by the
former smokers and current smokers at baseline or
during the follow-up period. It has been shown that
the risk associated with cigarette smoking is inﬂu-
enced by smoking burden, as determined by the
amount of cigarettes or packs of cigarettes smoked
per year, the number of years of smoking, and the
time since quitting smoking. It is known that the
decline in the risk after cessation is correlated to the
length of time since quitting smoking in patients
with post-myocardial infarction.25,26) However, in
relation to AF, when not mediated by myocardial
infarction, both current and past smoking have the
same harmful eﬀects, indicating that one should
never start smoking. (3) The asymptomatic recur-
rence of AF is a universal limitation for catheter
ablation of AF. Because we used only a one-day
Holter recording, recurrences of asymptomatic AF
might have been missed. (4) In this study, the reason
why the recurrence of AF occurred earlier in the
former smokers than in the current smokers, as
demonstrated in the Kaplan-Meier survival curve in
Figure 3, is unexplained.
Conclusion
We conclude that AF recurrence after PV isolation
is signiﬁcantly higher in smoking patients. The
substrate of AF may be worsened by exposure to
cigarette smoking.
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